MCL: Post-Remission, Skip Stem Cell Transplant? - Medscape
Dec 19, 2024 · Patients with mantle cell lymphoma (MCL) who show undetectable minimal residual disease (MRD) after initial treatment with chemotherapy show no significant overall or progression-free survival ...
Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
Sep 10, 2020 · Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and ...
Cure for Mantle Cell Lymphoma Within Reach, Says Expert
Jan 19, 2016 · "Mantle cell lymphoma is a rare disease, which has made it a challenge to study in clinical trials, but rapid advances have been achieved in the past 2 decades, and the future is very bright ...
Treatment Options in MCL: What Are the Best Practices? - Medscape
Sep 12, 2024 · Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer ...
ESMO Guideline for Mantle Cell Lymphoma - Medscape
Sep 25, 2014 · First International Guideline on MCL . Editor's Note: A new clinical practice guideline on mantle cell lymphoma (MCL) has recently been issued by the European Society for Medical Oncology (ESMO ...
Episode 1: Autologous Stem Cell Transplant for Mantle Cell …
Jan 31, 2023 · Mantle cell lymphoma has always been a particular interest of mine. I remember seeing some cases of mantle cell lymphoma as a fellow. This was about 25 years ago, and it was a fairly recently ...
FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma
Jan 27, 2023 · This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.
New Trials in Leukemia and Lymphoma: Could Your Patient …
Feb 28, 2024 · Relapsed or refractory mantle cell lymphoma. Adults facing one of these clinical scenarios can join an Academic and Community Cancer Research United open label, phase 2 trial examining the ...
'Profound' Results With Ibrutinib Add-On in Mantle Cell …
Jun 4, 2022 · Wang noted that SHINE is the first phase 3 study to examine ibrutinib plus BR as a first-line therapy in mantle cell lymphoma and involved patients with previously untreated stage II-IV disease ...
Breakthroughs in Mantle Cell Lymphoma From ASH 2022
Jan 4, 2023 · The beginning of the end for upfront stem cell transplants and chemotherapy, plus novel relapsed/refractory therapies, are among Dr Peter Martin's highlights in mantle cell lymphoma from ASH 2022.